ABSTRACT
procedures used (chorionic villus sampling and amniocentesis) 1, 2 . These diagnostic procedures are, therefore, reserved for women at high risk of fetal chromosomal aneuploidy.
A combined first-trimester risk assessment for trisomy 21 (T21) based on maternal age, nuchal translucency (NT) thickness, and levels of free beta-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A) has been offered to all pregnant women in Denmark since 2004, and more than 90% of women undergo the assessment [3] [4] [5] . About 5% of women are referred for invasive testing at a 1 in 300 risk cut-off 5 . The detection rate (DR) of T21 based on this combined first-trimester screening (cFTS) is about 90% 5 . The cFTS biomarkers are also associated with other chromosomal aneuploidies, especially trisomy 18 (T18) and trisomy 13 (T13) 6 .
Analysis of cell-free fetal DNA (cfDNA) in maternal blood has a reported DR above 99%, 96% and 91% for T21, T18 and T13, respectively, at a false-positive rate (FPR) of < 1%, in both high-and low-risk pregnancies 7, 8 . A contingent policy selecting women for cfDNA testing based on the estimated risk on conventional cFTS would retain the advantages of an early ultrasound examination, provide a risk assessment for all women and reduce the number of women referred for invasive testing. A limitation of this policy, however, is that offering invasive testing only to women identified as high risk by cfDNA testing would leave some phenotypically important chromosomal aneuploidies undetected 9 . Offering invasive testing to women with the highest cFTS risk would reduce this limitation and improve screening performance.
The primary aim of this study was to compare the screening performance for T21 between cFTS with referral for invasive testing at a T21 risk of ≥ 1 in 300, and contingent screening consisting of referral for invasive testing at a cFTS-T21 risk of ≥ 1 in 100 and referral for cfDNA testing at a cFTS-T21 risk of between 1 in 100 and 1 in 1000. Secondary aims were to compare the incidence of fetuses diagnosed with T18, T13 or sex chromosome aneuploidy, and examine the association between fetal fraction of cfDNA in maternal blood and maternal/fetal characteristics.
METHODS
Women aged ≥ 18 years with a singleton pregnancy, a cFTS risk for T21 of ≥ 1 in 1000 and no language barrier, were recruited consecutively for cfDNA testing by sonographers at two study sites in Copenhagen (Copenhagen University Hospitals, Rigshospitalet and Herlev and Gentofte Hospital) between August 2014 and May 2015. Of women with a cFTS-T21 risk ≥ 1 in 300, only those opting for invasive testing were included. Pregnancies with a vanishing twin or referrals from another hospital were excluded.
The combined risk assessment was based on maternal age, NT thickness at a crown-rump length of 45-84 mm and concentrations of PAPP-A and β-hCG. Maternal characteristics, and biochemical and ultrasonographic data were registered in Astraia software (Astraia Software GmBH, Munich, Germany) and the person-specific risk was calculated using formulae derived from The Fetal Medicine Foundation (www.fetalmedicine.org). In Denmark, all sonographers performing ultrasound examinations, including NT measurement, are certified in accordance with The Fetal Medicine Foundation guidelines. PAPP-A and β-hCG concentrations were converted to multiples of the median (MoM) by adjusting for ethnicity, weight, height, smoking status, method of conception and gestational age.
Blood samples for cfDNA testing were collected before invasive testing, if required, was performed. Analysis was performed by Ariosa ® (Roche) Diagnostics, Inc. (San Jose, CA, USA), using the Harmony Prenatal Test ® (Roche Molecular Systems, Inc., Indianapolis, IN, USA), while blinded to the cFTS risk assessment and karyotype results. A second blood sample was collected in cases in which the first one did not meet the laboratory requirements, e.g. there were > 7 days from blood draw to receipt of the sample, or in cases with hemolysis, insufficient fraction of fetal cfDNA (< 4%) or unusually high variance in cfDNA counts. The analysis was chromosome-selective using DANSR™ (Digital ANalysis of Selected Regions, Roche Molecular Systems) and included simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction [10] [11] [12] [13] [14] . FORTE™ (Fetal fraction Optimized Risk of Trisomy Evaluation, Roche Molecular Systems) was used to provide patient-specific risk assessments for T21, T18, T13 and sex chromosomal aneuploidies. cfDNA test results were registered in a local database. In case of a high risk for fetal aneuploidy, the woman was offered invasive testing including multiplex ligation-dependent probe amplification and chromosome analysis. Maternal chromosome analysis was offered in cases of discordant sex chromosomal aneuploidy results.
For all women undergoing cFTS risk assessment at the two study sites, information regarding the first-trimester screening and pregnancy outcomes, as well as pre-and postnatal karyotypes, was obtained from the Danish Fetal Medicine Database. All infants in Denmark are examined at birth by a midwife and 5 weeks after birth by a general practitioner. It is expected that infants with T21, T18 or T13 will be diagnosed within a few weeks after birth, as the phenotype is severely affected in these conditions. For the purposes of this study, liveborn infants without chromosomal analysis were considered euploid. Pregnancies with no chromosomal analysis, missing outcome, termination, miscarriage, intrauterine death (IUD) or a stillborn infant, as well as cases of mosaic T21, were excluded from the analysis of test performance.
The study was approved by the local ethics committee (H-1-2014-025) and the Danish Data Protection Agency cFTS-T21 risk <1 in 100 to ≥ 1 in 300 (n = 107):
Figure 1
Flowchart showing women who were included for cell-free DNA (cfDNA) testing following combined first-trimester screening (cFTS) for trisomy 21 (T21). T18, trisomy 18; T13, trisomy 13.
(03082/30-1280). Written informed consent was obtained from all participants.
Sample size
The selected cut-offs for the contingent strategy are based on a Danish register study 9 . The expected DR of T21 was 93% if women with a risk of ≥ 1 in 100 were referred for invasive testing and women with a risk of < 1 in 100 to ≥ 1 in 1000 were referred for cfDNA testing. In comparison, the expected DR was 88% with the current strategy, according to which women with a cFTS risk of ≥ 1 in 300 are referred for invasive testing. The sample size could not be based on a comparison of sensitivities owing to the low prevalence of T21 15 . To include at least 10 pregnancies with fetal T21, about 6000 women with a mean maternal age of 30 years (corresponding to an age-adjusted risk at 12 weeks' gestation of 1 in 626) should have a cFTS risk assessment for T21 16 . This corresponds to 600 women with a cFTS risk of ≥ 1 in 1000. This sample size would allow comparison of the expected specificities (the current strategy at 96% and the contingent strategy at 98%) at a 5% significance level and power of > 90%.
Statistical analysis
SAS ® Enterprise Guide (SAS Institute Inc., Cary, NC, USA) and STATA (StataCorp, College Station, TX, USA) were used for data analysis. Descriptive data are presented as mean ± SD or median (interquartile range (IQR)), as appropriate, for continuous variables and as n (%) for categorical variables. The performance of the screening strategies was evaluated by sensitivity (DR), specificity (1 -FPR), positive (PPV) and negative (NPV) predictive values, and compared using McNemar's test. Analysis of variance (ANOVA) or covariance (ANCOVA) was used for univariate regression analysis of associations between the fetal fraction and maternal or fetal characteristics. The fetal fraction was transformed with the natural logarithm to approach a Gaussian distribution. Variables of statistical significance in the univariate regression analysis were included in a multivariate regression analysis. For significant continuous variables, trend-tests were used to compare the proportion of women obtaining a result and the median fetal fraction across groups using Cuzick's extension of the Wilcoxon rank-sum test. The chi-square test or Fisher's exact test including odds ratio for obtaining a result was used as appropriate for significant categorical variables, and the Mann-Whitney test was used to compare the median fetal fraction; P < 0.05 was considered to indicate statistical significance.
RESULTS

Between 4 August 2014 and 22
May 2015, 6449 women underwent cFTS risk assessment. In this period, 869 women were found to have a combined risk of T21 of ≥ 1 in 1000 and 597 were included for cfDNA testing ( Figure 1 ). The combined risk of T21 was ≥ 1 in 300 and ≥ 1 in 100 in 32.7% (195/597) and 14.7% (88/597) of women, respectively. Fifty-eight women who were eligible for cfDNA testing chose not to participate in the study: 10 (17.2%) with a cFTS-T21 risk of ≥ 1 in 100, 12 (20.7%) with a risk of < 1 in 100 to ≥ 1 in 300 and 36 (62.1%) with a risk of < 1 in 300. Maternal and fetal characteristics of the total cohort and Values are mean ± SD, median (interquartile range) or %. *Height < 135 or > 220 cm was excluded. †Weight < 35 or > 250 kg was excluded. β-hCG, beta-human chorionic gonadotropin; PAPP-A, pregnancy-associated plasma protein-A; MoM, multiples of the median; NT, nuchal translucency thickness; T21, trisomy 21. of the women included for cfDNA testing are shown in Table 1 . A total of 6247 (96.9%) singleton pregnancies resulted in a live birth, 55 (0.9%) in termination of pregnancy, 27 (0.4%) in miscarriage and 13 (0.2%) in IUD or stillbirth, while pregnancy outcome was unknown in 107 (1.7%) pregnancies. Of these, pregnancies that went un-recruited or were ineligible, those with mosaic T21 and those without chromosomal analysis (liveborn infants were considered euploid if no karyotype was available) were excluded, leaving a total of 6066 pregnancies for the analysis of test performance.
Overall, a cfDNA risk for T21 was detected in 581 of the 597 (97.3%) samples, and a result was obtained using the first blood sample in 578 (96.8%) cases. In 15 cases, a cfDNA risk for T21 could not be determined after the first sampling owing to insufficient cfDNA or high variance in cfDNA counts ( Table 2 ). Of these, karyotype analysis was performed in eight cases and the result was abnormal in four (mosaic T21 (n = 1), T21 (n = 1), triploidy (n = 2)). A normal karyotype was found in both cases with hemolysis in the first blood sample. In one case in which it was not possible to obtain a result in two consecutive blood samples owing to high variance in cfDNA counts, further questioning revealed that the woman had had bone marrow transplantation; had this information been available before inclusion, the patient would not have been eligible for cfDNA testing.
Trisomy 21
The distribution of fetal chromosomal abnormalities according to cFTS and cfDNA risks of T21 is listed in Table 3 . In the study period, 24 fetuses were diagnosed with T21 in the total population, including two cases of mosaic T21 that were excluded from the test performance analysis. The expected number of fetuses with T21 at 12 weeks' gestation according to the age distribution of the whole population was 24 16 . The cFTS-T21 risk was ≥ 1 in 300 in all the pregnancies with fetal non-mosaic T21. Of these, 15 were included for testing by cfDNA analysis (risk range, 1 in 2 to 1 in 54). The cfDNA risk for T21 was > 99/100 in 13 cases, < 99/100 in one and was not obtained in one pregnancy owing to high variance in cfDNA counts. In the discordant case with a low cfDNA risk of T21 and a fetal fraction of 8.8%, a fetal heart beat had been visualized on the day of the NT scan but not on the following day at the time of invasive testing. The blood for cfDNA testing was collected in the morning on the day of planned invasive testing.
Sensitivity and specificity for the detection of non-mosaic T21 were 100% (95% CI, 78.2-100.0%) and 97.0% (95% CI, 96.6-97.5%), respectively, using the standard cFTS strategy, according to which all women with a T21 risk of ≥ 1 in 300 are referred for invasive testing ( Table 4 ). The CIs of the sensitivity, PPV and NPV of the cFTS strategy overlapped those of the contingent strategy (referral for invasive testing at a T21 risk of ≥ 1 in 100; referral for cfDNA testing at a T21 risk of < 1 in 100 to ≥ 1 in 1000), but the specificity of the contingent strategy was significantly higher (98.8% (95% CI, 98.5-99.1%); McNemar's test P < 0.0001).
Trisomies 18 and 13
In the total cohort, T18 was diagnosed in six pregnancies, with a cFTS risk for T18 ranging from 1 in 2 to 1 in 67. Of these, two pregnancies were eligible and one pregnancy was included for cfDNA testing and had a risk for T18 of > 99/100. T13 was diagnosed in two pregnancies (cFTS risk for T13 of < 1 in 1000 in both cases) and both were included for cfDNA testing, giving risks of T13 of > 99/100. The obtained combined risk of T21 had been intermediate (1 in 729) in one case and the woman was referred for chorionic villus sampling (CVS) owing to the high cfDNA risk (fetal fraction of 12.9%). At the time of CVS, a small empty gestational sac was seen next to the live fetus, which showed no phenotypical findings of T13. Karyotype analysis, however, confirmed the high cfDNA risk for T13 and the woman was referred for amniocentesis, which again confirmed fetal T13. This case was not excluded from analysis, as the empty gestational sac had not been seen at the time of the NT scan.
The overall sensitivity for the detection of T21, T18 and T13 was 94.4% (95% CI, 72.7-99.9%) and the overall specificity was 97.1% (95% CI, 96.6-97.5%) using the standard cFTS strategy. The CIs of the sensitivity, PPV and NPV of the cFTS strategy overlapped those of the contingent strategy, but the specificity of the contingent strategy was significantly higher (98.9% (95% CI, 98.6-99.1%); McNemar's test: P < 0.0001) ( Table 4) .
Sex chromosomal aneuploidies
The sex was identified correctly by cfDNA testing in 292 male and 285 female fetuses, and reported in one pregnancy with missing information on outcome (total n = 578). A risk of sex chromosomal aneuploidy was obtained in 576 pregnancies, while in two pregnancies a result of the XY analysis could not be obtained (low cfDNA risk of T21, T18 and T13, and fetal fractions of 9.5 and 10.2%, respectively); in these cases, the cFTS risks for T21 were 1 in 234 and 1 in 348, respectively, and both fetal karyotypes were euploid.
Nine women with a cFTS risk for T21 of ≥ 1 in 1000 were found to have a high risk of a fetal sex chromosomal aneuploidy on cfDNA analysis (Tables 3  and 5 ). Of three pregnancies with increased risk of 45,X, one was confirmed with invasive testing, one was diagnosed with 47,XXX and one had a normal female karyotype. The maternal karyotype was euploid in the case with 47,XXX. The fetal karyotype was euploid in three of four pregnancies with increased cfDNA risk of 47,XXX, and it was not analyzed in one. The maternal karyotype was analyzed in one case and was euploid. There was missing karyotype as well as missing outcome, termination, miscarriage, intrauterine death or stillborn infant in 115 cases. *One not tested with chromosome analysis. †Excluded from test performance analysis. ‡All with a combined risk of trisomy 18 (T18) > 1 in 100. §High risk for 45,X, but karyotype was 47,XXX. ¶Triploidy (n = 8), trisomy 22 (T22) (n = 2), deletion or duplication (n = 7). **Triploidy (n = 4), T22 (n = 1). SCA, sex chromosome aneuploidy; T13, trisomy 13. Data are given as % (95% CI). *P < 0.0001. Standard strategy: combined first-trimester screening (cFTS) for all women and invasive testing for women with cFTS risk ≥ 1 in 300. Contingent strategy: cFTS for all women with invasive testing for women with cFTS risk ≥ 1 in 100 and cfDNA testing for women with cFTS risk between 1 in 100 and 1 in 1000. Analyses are based on 6066 pregnancies (cFTS risk ≥ 1 in 100 (n = 88), cFTS risk ≥ 1 in 300 (n = 194), T21 (n = 15), T18 (n = 1), T13 (n = 2)). NPV, negative predictive value; PPV, positive predictive value. The cfDNA risk of 47,XXY was increased in two euploid male pregnancies but the maternal karyotypes were not analyzed. There were no registered false-negative cases of sex chromosomal aneuploidy. The FPR for the detection of sex chromosomal aneuploidy on cfDNA analysis was 1.2% (95% CI, 0.5-2.5%), as seven of 576 pregnancies were categorized at increased risk of a specific sex chromosomal aneuploidy but with discordant karyotype (excluding the one case at increased risk but unknown karyotype and including the discordant 45,X/47,XXX case as false positive; Table 5 ).
Fetal fraction and association with maternal and fetal characteristics
Median fetal fraction was 11.6% (IQR, 8.8-14.0%), and time for analysis and overall interval from blood sampling to obtaining the test result, in the 578 samples providing β-hCG, β-human chorionic gonadotropin; CRL, crown-rump length; IVF, in-vitro fertilization; NT, nuchal translucency; PAPP-A, pregnancy-associated plasma protein-A; T13, trisomy 13; T18, trisomy 18; T21, trisomy 21. Samples with no result due to hemolysis (n = 2) or transport delay (n = 2) are excluded. IQR, interquartile range; MoM, multiples of the median. a risk result after the first sampling, was 6 days (IQR, 5-7 days) and 11 days (IQR, 10-13 days), respectively.
The fetal fraction decreased significantly with maternal weight and increased significantly with levels of β-hCG and PAPP-A (both measured concentration and MoM), and among female fetuses in both univariate and multivariate analyses (Table 6 ). The fetal fraction decreased by about 1% per 10 kg (i.e. from 11.5% at 60 kg to 10.6% at 70 kg), increased by about 1% per 0.5 MoM increase in PAPP-A (i.e. from 10.5% at 0.5 MoM to 11.4% at 1.0 MoM), increased by about 0.4% per 0.5 MoM increase in β-hCG (i.e. from 10.1% at 0.5 MoM to 10.5% at 1.0 MoM) and was about 1% higher in pregnancies with female fetuses. The fetal fraction was not significantly associated with smoking in the multivariate analysis. No significant association was detected between fetal fraction and maternal height, age, crown-rump length, NT, parity, ethnicity, method of conception or fetal karyotype.
No test results were obtained in four aneuploid pregnancies. This was because of high variance in cfDNA counts in one pregnancy with non-mosaic T21 (diagnosed by CVS; maternal weight, 70.0 kg), and low fetal fraction in three pregnancies: one with mosaic T21 diagnosed by CVS (maternal weight, 111.5 kg) and two with triploidy (maternal weight, 60.0 and 68.0 kg) ( Table 3 ). There was no significant difference in the median fetal fraction between euploid and aneuploid pregnancies (11.1% vs 11.5%; P = 0.71), but the proportion of women for whom a cfDNA risk was obtained was significantly lower among the pregnancies with fetal aneuploidy, especially when excluding samples with no results owing to hemolysis (n = 2) or with a transport delay of > 7 days (n = 2) (84.6% vs 98.1%; P = 0.003; Table 7 ). The odds ratio for fetal aneuploidy among cases with no result compared with those with a result was 9.2 (95% CI, 2.7-31.1). Excluding pregnancies with any fetal aneuploidy (n = 22) from the regression analysis did not affect the association between fetal fraction and weight, β-hCG, PAPP-A or sex. The trends of obtained result and fetal fraction according to weight, levels of PAPP-A and β-hCG grouped according to the 25 th and 75 th percentiles, sex and karyotype are shown in Table 7 .
DISCUSSION
In this cohort study the screening performance of cFTS was compared with that of contingent cfDNA screening for the detection of T21, and no statistical difference was found with respect to sensitivity, PPV or NPV, but a higher specificity was observed when using contingent screening. The fetal fraction decreased with maternal weight, increased with both β-hCG and PAPP-A levels, and was higher in pregnancies with female fetuses. The proportion of women for whom a cfDNA result could be obtained decreased with increasing weight and was lower among pregnancies with fetal aneuploidy.
Two systematic reviews 7, 8 have shown that the accuracy of cfDNA testing for T21, T18 and T13 in both highand low-risk populations is better than that of cFTS. However, the included studies were rated with a high risk of bias owing to patient selection, timing of the cfDNA analysis, patient follow-up, publication bias and sponsor role 8 . The rate of test failure ranged from 0% to > 12%, and these were excluded from the meta-analyses. Including test failures resulted in a decrease in sensitivity of 1.7% for T21, 1.6% for T18 and 7.1% for T13, and the specificity decreased by nearly 2% for all trisomies 8, 17 . Our rate of test failure from the first sampling was 3.2%. Like others 18, 19 , we found an increased rate of aneuploidy (T21, mosaic T21 and triploidy) among pregnancies with no cfDNA result. The association between test failure and aneuploidy has mainly been observed in pregnancies with T18 and T13, owing to low fetal fraction [19] [20] [21] [22] , which may be related to the smaller placentae often seen in these pregnancies 23 . Other factors affecting the failure rate, such as maternal weight and levels of PAPP-A and β-hCG, should be considered before classifying a pregnancy with test failure as high risk and referring for further ultrasound assessment and eventually invasive testing [18] [19] [20] [21] [22] 24, 25 . However, the association with aneuploidy is of clinical relevance and might increase the overall rate of invasive testing. Thus our results and those of others 18, 19 indicate that test failures should not be ignored when discussing the performance of cfDNA testing, even though the cfDNA test used in our study was limited to screening for T21, T18, T13 and sex chromosomal aneuploidies.
Including test failures as false positives to mimic a conservative scenario in which all women with a test failure were offered invasive testing in our study would not have changed the sensitivity of contingent screening for T21, as the combined risk was ≥ 1 in 100 in the affected pregnancies with no cfDNA result. The specificity would have decreased by 0.3%, but would still have been higher than that of the current strategy (P < 0.0001). Consequently, a shift from cFTS to contingent screening would result in a lower FPR without affecting the DR of T21. In our study, 8.4% (509/6066) women had a cFTS-T21 risk of between 1 in 100 and 1 in 1000. The significant decrease in FPR from 3.0% to 1.2% corresponds to avoiding one invasive test in a non-T21 pregnancy at the cost of nearly five cfDNA tests (1.8%/8.4%). The rate of invasive testing decreased by 50% after the introduction of cFTS in Denmark and a further reduction would necessitate a discussion of centralization of these procedures 4 . Contingent cfDNA screening has been investigated by others using different cut-offs. A UK study with cut-offs at 1 in 150 and 1 in 1000 found 100% sensitivity and 99.6% specificity for cfDNA testing in detecting aneuploidy 26 , results that are comparable with ours. Gil et al. 27 , using cut-offs of 1 in 100 and 1 in 2500, reported a sensitivity of 91.5% (43/47) for T21 and 94.7% (71/75) for T21, T18 and T13. The invasive testing rate in the high-risk group was reduced (from 2.6% to 1.7%), but not to the expected extent. Their study demonstrates that the performance of such a strategy in clinical practice depends on parental decisions about uptake of screening and diagnostic testing. In the Dutch Trident study, 85.7% of women with a risk above 1 in 200 chose cfDNA testing, resulting in 96.7% sensitivity and 99.9% specificity for the detection of T21 28 . Our study was not designed to compare the current cFTS strategy with cfDNA testing in the entire population, but it should be noted that all pregnancies with fetal non-mosaic T21 had a cFTS-T21 risk of > 1 in 100, and were detected using contingent screening as well as by using the current strategy, but two cases of T21 could have gone undetected if women were offered cfDNA testing as the first-line test without further investigation. In addition, screening based on first-trimester ultrasound as first-line has the potential for the early detection of other phenotypically important aneuploidies.
In our study, seven of 576 pregnancies had a high cfDNA risk of a sex chromosomal aneuploidy, which was discordant with the chromosomal analysis, giving a FPR of 1.2%. This rate is higher than that found in a systematic review (0.004% (95% CI, 0.0-0.08%)) 7 . The true FPR may, however, be higher owing to the presence of an ascertainment bias of sex chromosomal aneuploidies combined with a lack of confirmatory karyotyping and incomplete follow-up in many studies. Bianchi et al. 29 estimated the FPR to be in the range of 0.26-1.05% by considering cases with a missing outcome as, first, true-positive cases and, second, false-positive cases. The ethical implications of screening for conditions with only a minor impact on phenotype should be considered before adding screening for sex chromosomal aneuploidies to screening for T21, T18 and T13 7 .
Strengths and limitations of the study
A high risk of bias should have been prevented by some features of our study 7, 8 , for example, that it was performed in a clinical setting with first-trimester blood sampling before invasive testing, that the analyses were performed blinded to the cFTS risk and chromosome analyses and that no commercial funding was obtained. Furthermore, we excluded pregnancies with no chromosomal analysis and missing outcome, termination, miscarriage or IUD from the analysis. The paired study design ensured that the two strategies were compared within the same population. However, only women with a cFTS risk of ≥ 1 in 1000 were included for cfDNA testing, which may bias the conclusions regarding the maternal/fetal associations and fetal fraction. Only the risk for T21 was used as an inclusion criterion because the primary aim was to investigate screening performance for this trisomy.
In this study liveborn infants with no chromosomal analysis were considered to be euploid. This is a limitation regarding sex chromosomal aneuploidies, but infants with T21, T18 or T13 are expected to be diagnosed shortly after birth.
Conclusion
When compared with cFTS, contingent screening for T21, T18 and T13 increased specificity at no loss of sensitivity. Introducing a contingent approach would markedly reduce the number of invasive tests.
